Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 9/20 | 0.87 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.87 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | BRAF | P15056 | 2/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534284 | 0.93 | PTK2 (1.00) | PTK2PTK2BMAPK14MAPK13MAPK12 | |
| SCHEMBL3532066 | 0.92 | PTK2 (0.86) | PTK2PTK2BMAPK14MAPK13MAPK12 | |
| SCHEMBL3534301 | 0.92 | PTK2 (0.89) | PTK2PTK2BMAPK14MAPK13MAPK12 | |
| SCHEMBL3530115 | 0.90 | PTK2 (0.84) | PTK2PTK2BMAPK14MAPK13MAPK12 | |
| SCHEMBL3532220 | 0.88 | PTK2 (0.87) | PTK2PTK2BMAPK14MAPK13MAPK12 | |
| SCHEMBL3528327 | 0.88 | PTK2 (0.78) | PTK2PTK2BMAPK14MAPK13MAPK12 | |
| SCHEMBL3532354 | 0.85 | PTK2 (0.66) | PTK2PTK2BMAPK14MAPK13MAPK12 | |
| SCHEMBL3537558 | 0.84 | PTK2 (0.63) | PTK2PTK2BMAPK14MAPK13MAPK12 | |
| SCHEMBL3533020 | 0.82 | PTK2 (0.60) | PTK2PTK2BMAPK14MAPK13MAPK12 | |
| SCHEMBL3528696 | 0.81 | PTK2 (0.59) | PTK2PTK2BCYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912998-B1 | PYRAZOLE DERIVATIVES HAVING TYROSINKINASE ACTIVITY | MERCK PATENT GMBH (DE) | 2013-03-06 | — | — | EP | claimed |
| US-7662827-B2 | Pyrazole derivatives having tyrosine kinase inhibitory activity | MERCK PATENT GMBH (DE) | 2010-02-16 | — | — | US | claimed |
| US-20080207647-A1 | Pyrazole Derivatives Having Tyrosine Kinase Activity | MERCK PATENT GMBH (DE) | 2008-08-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207647-A1 | Pyrazole Derivatives Having Tyrosine Kinase Activity | TIE1, FER, ROS1 | PTK2 152/4885PTK2B 24/4885MAPK14 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.